Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Medical Supplies Industry Analysis

UpdatedDec 23, 2025
DataAggregated Company Financials
Companies41
  • 7D0.4%
  • 3M16.0%
  • 1Y-11.2%
  • YTDn/a

Over the last 7 days, the Medical Supplies industry has remained flat. Unfortunately though, the industry is down 11% over the past 12 months. Earnings are forecast to grow by 27% annually.

Industry Valuation and Performance

Has the U.S. Medical Supplies Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 23 Dec 2025US$131.2bUS$63.5bUS$958.1m26.6x136.9x2.1x
Thu, 20 Nov 2025US$67.3bUS$36.1b-US$272,672,280.0020.9x-246.7x1.9x
Sat, 18 Oct 2025US$66.3bUS$36.1b-US$1,348,148,630.0021.6x-49.2x1.8x
Mon, 15 Sep 2025US$66.5bUS$36.1b-US$1,395,631,837.0021.8x-47.7x1.8x
Wed, 13 Aug 2025US$65.8bUS$36.0b-US$1,418,409,228.0023.3x-46.4x1.8x
Fri, 11 Jul 2025US$77.8bUS$36.0b-US$853,313,666.3927.2x-91.1x2.2x
Sun, 08 Jun 2025US$74.3bUS$36.0b-US$853,313,415.2927.2x-87x2.1x
Tue, 06 May 2025US$76.3bUS$35.9b-US$686,648,534.0024.2x-111.1x2.1x
Thu, 03 Apr 2025US$78.6bUS$35.9b-US$625,773,350.0026.1x-125.6x2.2x
Sat, 01 Mar 2025US$84.5bUS$35.7b-US$604,963,882.0027x-139.7x2.4x
Mon, 27 Jan 2025US$92.0bUS$35.5bUS$709.3m28.7x129.7x2.6x
Wed, 25 Dec 2024US$87.6bUS$35.5bUS$1.2b31.9x75.4x2.5x
Fri, 22 Nov 2024US$92.7bUS$35.4bUS$1.1b35.8x82.1x2.6x
Sun, 20 Oct 2024US$99.5bUS$35.0bUS$1.6b36.7x61.3x2.8x
Tue, 17 Sep 2024US$99.7bUS$35.0bUS$1.6b41.7x60.8x2.8x
Thu, 15 Aug 2024US$90.4bUS$35.1bUS$1.6b40.8x54.9x2.6x
Sat, 13 Jul 2024US$93.8bUS$34.8bUS$2.1b41.2x44.5x2.7x
Mon, 10 Jun 2024US$91.7bUS$34.8bUS$2.1b40.6x43.5x2.6x
Wed, 08 May 2024US$93.5bUS$34.6bUS$2.3b40.5x41.2x2.7x
Fri, 05 Apr 2024US$94.7bUS$34.2bUS$2.1b42.6x45.9x2.8x
Sun, 03 Mar 2024US$84.3bUS$26.0bUS$640.8m41.8x131.5x3.2x
Tue, 30 Jan 2024US$80.5bUS$26.2bUS$280.6m40.9x286.9x3.1x
Thu, 28 Dec 2023US$84.9bUS$26.2bUS$242.3m40.5x350.4x3.2x
Sat, 25 Nov 2023US$75.1bUS$26.1bUS$223.4m41.7x336.4x2.9x
Mon, 23 Oct 2023US$78.8bUS$25.9b-US$705,469,439.0035.2x-111.7x3x
Wed, 20 Sep 2023US$86.8bUS$25.8b-US$702,386,232.0034.6x-123.6x3.4x
Fri, 18 Aug 2023US$94.4bUS$25.7b-US$689,292,856.0033.7x-137x3.7x
Sun, 16 Jul 2023US$100.2bUS$25.1b-US$585,995,701.0035.2x-170.9x4x
Tue, 13 Jun 2023US$93.0bUS$25.6b-US$571,795,238.0036.8x-162.6x3.6x
Thu, 11 May 2023US$95.8bUS$25.5b-US$529,145,076.0039.5x-181x3.8x
Sat, 08 Apr 2023US$94.4bUS$25.4b-US$331,237,864.0046.2x-284.9x3.7x
Mon, 06 Mar 2023US$94.7bUS$25.5b-US$488,907,803.0044x-193.7x3.7x
Wed, 01 Feb 2023US$90.4bUS$25.1b-US$38,374,212.0038.8x-2355.8x3.6x
Fri, 30 Dec 2022US$78.2bUS$25.0bUS$24.3m34.3x3214.7x3.1x
Price to Earnings Ratio

3214.7x


Total Market Cap: US$78.2bTotal Earnings: US$24.3mTotal Revenue: US$25.0bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Medical Supplies Industry Price to Earnings3Y Average -54.3x202320242025
Current Industry PE
  • Investors are optimistic on the American Health Care Supplies industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 137x which is higher than its 3-year average PE of -54.3x.
  • The 3-year average PS ratio of 2.8x is higher than the industry's current PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Health Care Supplies industry have grown 240% per year over the last three years.
  • Revenues for these companies have grown 36% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does U.S. Medical Supplies compare with similar industries?

US Market0.99%
Healthcare0.29%
Medical Equipment0.68%
Medical Supplies0.37%
Medical Equipment0.70%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
COO Cooper CompaniesUS$83.842.8%
+US$452.7m		-9.4%PE43.8x
ESTA Establishment Labs HoldingsUS$76.616.4%
+US$133.1m		81.8%PS11.7x
LNTH Lantheus HoldingsUS$68.012.2%
+US$95.5m		-25.3%PE26.9x
UFPT UFP TechnologiesUS$229.675.4%
+US$91.4m		-9.0%PE26.4x
MMSI Merit Medical SystemsUS$87.921.7%
+US$89.5m		-9.9%PE44x

Latest News

RXST
US$12.23
RxSight
7D
-2.3%
1Y
-64.6%
ALGN
US$159.28
Align Technology
7D
-2.1%
1Y
-23.3%

ALGN: Q3 Volume Gains Will Support Renewed Confidence In Upcoming Revenue Ramp

Analysts have modestly raised their price target on Align Technology to $200 from $190, reflecting improved confidence in management's restored revenue visibility and Q4 execution following broad-based Q3 volume upside, even as valuation assumptions and long term growth forecasts remain largely unchanged. Analyst Commentary Recent Street commentary on Align Technology reflects a more constructive stance on near term execution, balanced by lingering questions around the durability of growth and visibility into 2025.
XRAY
US$11.26
DENTSPLY SIRONA
7D
-1.2%
1Y
-40.6%

XRAY: Longer Turnaround And CFO Transition Will Shape Risk Reward Ahead

The analyst price target for Dentsply Sirona has been reduced from $14 to $11 as analysts factor in softer growth, compressed margins, a higher perceived risk profile, and a longer dated turnaround, partially offset by a higher expected future P E multiple. Analyst Commentary Recent Street research reflects a more cautious stance on Dentsply Sirona, with several bearish analysts trimming price targets and tempering expectations for the pace of any recovery.
ESTA
US$76.61
Establishment Labs Holdings
7D
6.4%
1Y
81.8%

ESTA: Positive EBITDA And U S Expansion Will Support Measured Forward Outlook

Analysts have modestly increased their price target for Establishment Labs Holdings to approximately $80 per share from about $74, citing stronger than expected Q3 results, the company's first quarter of positive EBITDA, as well as growing confidence in sustained revenue growth and U.S. Motiva sales expansion. Analyst Commentary Street research following the Q3 print reflects a predominantly constructive stance on Establishment Labs, with analysts highlighting both upside drivers and lingering risks that could influence valuation and execution.
NEOG
US$7.13
Neogen
7D
4.1%
1Y
-41.2%

Neogen Corporation (NASDAQ:NEOG) Shares Fly 34% But Investors Aren't Buying For Growth

Dec 19
Neogen Corporation (NASDAQ:NEOG) Shares Fly 34% But Investors Aren't Buying For Growth
LNTH
US$68.01
Lantheus Holdings
7D
2.2%
1Y
-25.3%

LNTH: Future Earnings Will Rebound As Organic Growth Visibility Strengthens

Analysts have modestly lifted their price target on Lantheus Holdings to $82.29 from $80.93, citing a slightly lower discount rate, an improved profit margin outlook, and a firmer future P/E multiple, even as revenue growth expectations moderate. Analyst Commentary Recent Street research on Lantheus reflects a more balanced stance, with the modest price target lift occurring alongside at least one high profile downgrade.
SOLV
US$80.78
Solventum
7D
-1.4%
1Y
21.2%
COO
US$83.84
Cooper Companies
7D
2.8%
1Y
-9.4%
STAA
US$24.20
STAAR Surgical
7D
2.7%
1Y
0.1%
OSUR
US$2.41
OraSure Technologies
7D
-3.6%
1Y
-33.4%
KIDS
US$17.36
OrthoPediatrics
7D
-3.5%
1Y
-23.3%

KIDS: Reset Expectations Will Support Upside From Core High-Margin Franchise

Analysts trimmed their OrthoPediatrics price targets by roughly $6 to $10 per share across the Street, citing lowered revenue growth forecasts, below consensus Q3 results, and more conservative long term guidance, even as they maintained confidence in the company’s core, higher margin businesses. Analyst Commentary Street research following OrthoPediatrics' preliminary Q3 update reflects a mix of near term caution and longer term optimism, with price targets reset lower but most ratings remaining positive.
HAE
US$80.36
Haemonetics
7D
-0.9%
1Y
3.8%

HAE: Broad Outperformance And Achievable Hospital Guidance Will Support Gradual Share Recovery

Analysts have modestly raised their price target on Haemonetics to approximately $86 from about $85, citing broad-based outperformance, more achievable Hospital guidance, and an upgraded FY26 sales outlook that supports a gradual recovery in the shares. Analyst Commentary Bullish Takeaways Bullish analysts highlight that the price target increase toward the high $80s reflects growing confidence in the company’s ability to sustain outperformance across all operating segments.
CERS
US$2.12
Cerus
7D
5.5%
1Y
34.2%

Cerus Corporation (NASDAQ:CERS) Stock Catapults 31% Though Its Price And Business Still Lag The Industry

Dec 04
Cerus Corporation (NASDAQ:CERS) Stock Catapults 31% Though Its Price And Business Still Lag The Industry
UFPT
US$229.67
UFP Technologies
7D
5.4%
1Y
-9.0%
MMSI
US$87.92
Merit Medical Systems
7D
1.7%
1Y
-9.9%
AVNS
US$11.38
Avanos Medical
7D
-2.1%
1Y
-29.0%